← Browse by Condition
Medical Condition

gliomas

Total Trials
3
Recruiting Now
3
Trial Phases
EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for gliomas sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — gliomas Clinical Trials

How many clinical trials are currently recruiting for gliomas?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for gliomas, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for gliomas?
gliomas research spans Phase 1 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a gliomas clinical trial?
Eligibility criteria for gliomas trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Top Sponsors
JIANG LONGWEI 1 trial
Second Affiliated Hospital, School of Medicine, Zhejiang University 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT06828341 EARLY_Phase 1
Recruiting

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

Enrollment
3 pts
Location
China
Sponsor
JIANG LONGWEI
View Trial →
NCT07198256
Recruiting

AI-assisted Diagnosis of Malignant Brain Tumors

Enrollment
3,000 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
View Trial →
NCT05804227 EARLY_Phase 1
Recruiting

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology